Pseudo-endophthalmitis after intravitreal injection of triamcinolone
about
Emerging therapies for neovascular age-related macular degeneration: state of the artIntravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study.Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system.Short-term efficacy of intravitreal triamcinolone acetonide for macular edema secondary to retinal vein occlusion that is refractory to intravitreal bevacizumab.Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration.Immunological factors in the pathogenesis and treatment of age-related macular degeneration.Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy.National survey of the technique of intravitreal triamcinolone injection in the United Kingdom.Transport barriers in transscleral drug delivery for retinal diseases.Endophthalmitis after intravitreal injections.Endophthalmitis following intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration.Drug safety evaluation of intravitreal triamcinolone acetonide.Sterile endophthalmitis after intravitreal injections.Sterile endophthalmitis rates and particle size analyses of different formulations of triamcinolone acetonide.Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedemaComparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use.Pseudohypopyon after intravitreal triamcinolone injection for the treatment of pseudophakic cystoid macular oedema.Glucocorticoids induce transactivation of tight junction genes occludin and claudin-5 in retinal endothelial cells via a novel cis-element.Pharmacotherapeutic efficacy of preservative-free intravitreal triamcinolone acetonide.Ocular-hypertensive response and corneal endothelial changes after intravitreal triamcinolone injections in Chinese subjects: a 6-month follow-up study.Intravitreal preservative-free triamcinolone acetonide for the treatment of macular oedema.Phacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: a 6-month prospective pilot study.Two non-infectious forms of endophthalmitis after intravitreal triamcinolone and cataract extraction.Steroid hypopyon following intravitreal triamcinolone acetonide injection in a pseudophakic patient.Sterile endophthalmitis following intravitreal injection of triamcinolone acetonide.Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration.Ptosis following an intravitreal injection of triamcinolone acetonide.Clinical Outcomes of Intravitreal Preservative-Free Triamcinolone Preparation (Triesence®) for Cystoid Macular Oedema and Inflammation in Patients with Uveitis.Vitreous opacities after intravitreal triamcinolone injection- a case report.Intravitreal steroids for the treatment of retinal diseases
P2860
Q28253918-D55BD2DC-1013-4385-A0E2-D64A8BE58D93Q33206078-AFA4ECBC-7EAA-4607-AD7C-F2D341F6EBF8Q35164657-A3D7A870-4FAF-43FA-B308-CE292B750104Q35189176-BF1367F5-D598-491D-9B17-19B498525515Q35592674-C36F1C11-064F-42BC-A864-52B1E348C4DBQ36086191-A7C2D898-050E-4D2A-97D4-F31EA33D444DQ36311041-E372188A-09D2-4B53-98B0-A4BD383104FBQ36378901-BEFD4730-66B0-4507-9338-60B8EDC2939BQ36939032-C15BB57C-1840-49B3-A4B3-9804611DCB14Q37544827-174DCF12-870C-4817-A0AB-807A3CE22362Q37879167-C0A90D75-1F26-49B4-B87C-F45789E0685BQ37953969-FFA492D1-B436-44CF-9F14-34ED058649BCQ38042910-4AA88046-5BC1-4D7F-B3A9-FA42025DB9E6Q40821399-7AA9E97D-A14A-4958-AFB6-7F9325879E48Q42116404-D26DEAAE-A027-48FA-940B-15CC23F93762Q43006884-37DA1872-265A-430B-9849-BDE86DEE1091Q43007812-82E80738-9CA9-49A2-BF69-B9C0B25C2E7EQ43212996-C6F75027-C273-4BE9-A2A6-763546910803Q43225793-120F418C-E47D-4A1C-B300-EA0ADCAC5A4DQ44927521-0322ECD2-F13E-4F6F-B419-A69038CF93AAQ45032874-7BF4543D-1BDB-4B39-AF78-D4211EF866A7Q45075982-206CDEEE-0121-436E-8C56-E4A302DD8780Q46413338-ED1BA08C-36B9-44BD-B965-A43CBC1FDB98Q46600808-3233C5E3-C98E-42DA-9AFD-ABF6516DA5E0Q46700893-6611D095-F652-49DD-8A01-086AD056E0A0Q46893247-1D99D479-F0C3-4BD5-8B94-C36E5CFBD086Q46960849-77F60D79-7CF3-4FFF-BAD5-B1B57127ED32Q50789266-98712213-DEF1-4AA4-8A87-6D5055DC260FQ55442271-768B083B-E2D6-49DA-BD3D-147E58D39DC2Q59101228-C4104CC7-9D26-4138-AC95-7CC886DB209A
P2860
Pseudo-endophthalmitis after intravitreal injection of triamcinolone
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Pseudo-endophthalmitis after intravitreal injection of triamcinolone
@ast
Pseudo-endophthalmitis after intravitreal injection of triamcinolone
@en
type
label
Pseudo-endophthalmitis after intravitreal injection of triamcinolone
@ast
Pseudo-endophthalmitis after intravitreal injection of triamcinolone
@en
prefLabel
Pseudo-endophthalmitis after intravitreal injection of triamcinolone
@ast
Pseudo-endophthalmitis after intravitreal injection of triamcinolone
@en
P2860
P356
P1476
Pseudo-endophthalmitis after intravitreal injection of triamcinolone
@en
P2093
F K P Sutter
M C Gillies
P2860
P304
P356
10.1136/BJO.87.8.972
P407
P577
2003-08-01T00:00:00Z